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1 Introduction
The increasing needs of personalized therapies have re-
cently stimulated impressive advances in research and de-
velopment of portable point-of-care biosensors for real-
time monitoring as well as biosensors for drug develop-
ment [1, 2].
Enzymatic amperometric biosensors based on the
enzyme family cytochrome P450 (CYP) have drawn in-
creasing attention because CYP is a monooxygenase
enzyme primarily involved in the metabolism of bioactive
metabolites and hydrophobic xenobiotics such as drugs,
environmental pollutants and steroids [3]. The 3D struc-
ture of the enzyme is illustrated in Scheme 1A.
CYP catalyses the monooxygenase reaction, a two-elec-
tron reaction where the electrocatalytic transformation of
a substrate is coupled to the electrocatalytic reduction of
oxygen, according to the general equation:
RHþO2 þ 2e¢ þ 2Hþ ! ROHþH2O
A substrate (RH) is hydroxylated (ROH) through the
insertion of one oxygen atom into the substrate, while the
second atom of oxygen is reduced to water [4]. The two
electrons necessary for the monooxygenation are provid-
ed by the redox reaction of the heme group in the active
site of the CYP (Scheme 1A), which is in-vivo activated
through electron transfer from its redox partners: two
electrons derived from NAD(P)H are transferred to the
CYP active site via the electron transport protein, cyto-
chrome P450 reductase (CPR) [6]. The direct immobiliza-
tion of CYP on an electrode overcomes the need for
NAD(P)H and CPR, as the electrons needed for the
redox reaction of the heme group are directly supplied by
the electrode [4, 5,7,8].
Another approach is the electrode functionalization
with microsomes containing both CYP and CPR
(msCYPs). msCYPs are commonly used in the industry
for drug development [2]. As reported in [2,7,9], the dis-
covery that microsomes are as effective as recombinant
CYPs in enabling direct electrochemistry on electrodes
promoted an increasing interest in biosensors based on
microsomes-CYP, as the production of microsomes is
cheaper than recombinant CYPs. In a previous study [9]
msCYPs were immobilized on a polycation-coated elec-
trode and the authors proved that the direct electron
transfer occurred according to the natural electron trans-
fer path (electrode!CPR!CYP). Moreover, a more
recent work [10] proved that, in presence of a substrate,
the amount of metabolite formation in the microsomes
containing the reductase was almost double respect to
what obtained with CYP alone. The authors concluded
that the electron transfer from the electrode to the CPR
and then to the CYP is a more efficient pathway than the
direct electron supply to the CYP. In this work the au-
thors also showed that a hydrophobic electrode surface
facilitates the immobilization of msCYP, because of the
presence of hydrophobic regions in the surface structure
of CYP, CPR and the lipids that compose the microsome.
With cyclic voltammetry (CV) or other electro-analyti-
cal techniques, it is possible to apply a potential to the
immobilized CYP and record the current that is pro-
duced. This current can be attributed to the reduction of
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Abstract : In this work we present an investigation on the
behavior of microsomes containing human cytochrome
P450 in cyclic voltammetry for drug detection. The micro-
somes are adsorbed on the surface of multi-walled carbon
nanotubes by drop-casting. We demonstrate that the hy-
drophobic and highly electroactive surface of multi-
walled carbon nanotubes enables to distinguish more
clearly the contributions in reduction peak current attrib-
uted to the enzymatic components of microsomes. Vol-
tammetric measurements were performed under several
experimental conditions with two cytochrome P450-iso-
forms, 1A2 and 3A4. We show that the reduction current
for the component of cytochrome P450-microsome linear-
ly increases in the presence of a substrate.
Keywords: Cytochrome P450 · Drugs · Electrochemical biosensors · Carbon nanotubes · Purified cytochrome P450
www.electroanalysis.wiley-vch.de Ó 2015 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim Electroanalysis 2015, 27, 1507 – 1515 1507
Full Paper
the active site of the enzyme and it will increase in pres-
ence of a CYP substrate, e.g. a drug, or oxygen [6,11].
The oxidation/reduction of the heme group of CYP re-
sults in CV peaks at positions that can vary according to
the way the enzyme is immobilized and the presence of
a nanostructure, or the electrode material [5, 12], as re-
ported in many works of biosensors based on CYP1A2
and CYP3A4 [3,5,8,9,13,14,15,16,17,18,19,20,21,22].
From this analysis, it emerges that for each electrode
modification and CYP preparation it is necessary to iden-
tify the voltammetric peaks due to the reduction of CYP.
We report in this paper an enhanced electron transfer
in CV from the electrode to the microsome containing
CYP and CPR, by creating a hydrophobic and highly
electroactive surface with drop-cast multiwalled carbon
nanotubes (MWCNTs) on a screen-printed electrode
(SPE). Scheme 1B shows the scheme for the electrode
functionalization. The two arrows represent the electron
transfer (e¢) between the electrode and the protein. The
enhanced electron transfer to the heme-enzyme results in
a higher reduction current that enables to distinguish
more clearly the contributions in current attributed to the
redaction peaks of the microsome components, CYP and
CPR. Voltammetric measurements were performed under
several experimental conditions with microsomes of two
CYP-isoforms, CYP1A2 and CYP3A4. We also immobi-
lized on a MWCNT-SPE purified CYP3A4 (without
CPR) and purified CPR (without CYP3A4) and con-
firmed by CV the position of the reduction peaks of the
two components.
Moreover, we confirm that the reduction current for
the CYP component of the msCYP increases in the pres-
ence of a substrate (i.e. a drug) as has previously been
shown in other studies involving microsomal CYPs
[9,10].
2 Experimental
2.1 Reagents and Chemicals
MWCNTs (~10 nm diameter and ~1–2 mm length) with
5% COOH groups content were purchased as a powder
(90% purity) from DropSens.
Microsome containing cytochrome P4501A2
(msCYP1A2) and microsome containing cytochrome
P4503A4 (msCYP3A4) were purchased from Sigma-Al-
drich (St. Gallen, Switzerland) as isozyme microsomes
with recombinant human CYP1A2 (or CYP3A4), re-
combinant rabbit NADPH-P450 reductase, and cyto-
chrome b5 (0.5 nmole of cytochrome P450 isozyme in
100 mM potassium phosphate, pH 7.4.) and used as re-
ceived. All experiments were carried out in a 100 mM
phosphate buffered saline solution (PBS, pH 7.4) as sup-
porting electrolyte.
The drugs Naproxen [(S)-6-methoxy-a-methyl-2- naph-
thalene acetic acid] (NAP) and Ifosfamide (IFO), pur-
chased as a powder from Sigma-Aldrich, were dissolved
in chromatography grade methanol and milliQ water re-
spectively.
CHAPS 3-[(3-cholamidopropyl)-dimethylammonio]-1-
propansulfonat was purchased from Applichem GmbH
(Darmstadt, Germany). HisPur nickel nitrilotriacetic acid
(Ni-NTA) beads were ordered from Thermo Fisher Scien-
tific (Waltham, USA). CM macro-prep ion exchange sup-
port was ordered from Biorad (Hercules, USA). E. coli
HMS 174 (DE3) was ordered from Merck (Darmstadt,
Germany). The diethylaminoethanol (DEAE) sepharose
fast flow and adenosine 2’,5’-diphosphate agarose sup-
ports were both ordered from Sigma-Aldrich (St. Louis,
USA). DOPC (1,2-di-(9Z-octadecenoyl)-sn-glycero-3-
phosphocholine) was purchased from Avanti Polar Lipids
(Alabaster, USA).
EDTA (ethylenediaminetetraacetic acid) and DTT (di-
thiothreitol) were purchased from Sigma-Aldrich. Hydro-
gen peroxide (30%vol) was purchased from Sigma-Al-
Scheme 1. A) Structure of CYP (the isoform 1A2, from PDBe Protein Data Bank Europe), with a closer view of the heme group in
the substrate-binding cavity. B) Scheme of the electrode functionalization with drop-cast MWCNTs and msCYP (here generically
named “cytochrome P450”).
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drich and diluted to the desired concentration. HEPES
(4-(2-hydroxyethyl) piperazine-1-ethane sulfonic acid)
was purchased from Thermo Fisher Scientific (Waltham,
USA).
2.2 Expression and Purification of CYP3A4 and
Cytochrome P450 Reductase
The construct pSE3A4 expressing human CYP3A4 was
described previously [23, 24]. It contains 4 histidine resi-
dues at the C terminus of the CYP3A4 coding sequence.
Briefly, freshly transformed E.coli Topp3 cells were in-
duced with 0.5 mM isopropyl b-d-1-thiogalactopyranosid
(IPTG) and the CYP3A4 construct expressed for 48–
72 hours before cells were lysed by sonication and expres-
sion levels quantified by reduced carbon monoxide bind-
ing [25]. Solubilized membranes containing the enzyme
were purified via nickel-affinity chromatography using
Ni-NTA beads and anion exchange chromatography
using CM macro-prep ion exchange support. Human
P450 oxidoreductase from the construct CPR [26] was ex-
pressed in E. coli HMS 174 (DE3) and captured on an
Fig. 1. Reduction current peaks from CV after background subtraction, for msCYP3A4 on a MWCNT-modified SPE (A), for
a MWCNT-modified SPE without protein (B), for msCYP3A4 on a bare-SPE (C), for msCYP3A4 on a bare-SPE in the presence
(black points) and absence (blue points) of oxygen (D) and for the purified proteins (pCYP3A4 and pCPR) on MWCNT-modified
SPEs (E). Symbols used: cytochrome P450 (CYP), cytochrome P450 reductase (CPR), carbon-nanotubes (CNT), background (BKG).
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anion exchange chromatography support (DEAE sephar-
ose fast flow) and polished on an adenosine 2’,5’-diphos-
phate agarose support.
The purity of the enzymes was analyzed via SDS-gel
electrophoresis and absorption spectroscopy. The record-
ed spectra were compared to available standard spectra
of purified CYP3A4 (pCYP3A4) and purified CPR
(pCPR) and quantified using spectralab software [27].
The concentration of pCYP3A4 (77 mM) and pCPR
(101 mM) were reduced to 20 mM by diluting the protein
preparation in a 50 mM (pH 7.4) potassium phosphate
buffer containing 0.5 mM EDTA.
The reconstituted systems (recCYP3A4 and recCPR
with cytochrome b5) were prepared by diluting the follow-
ing reagents in our buffer (100 mM HEPES pH7.4, 1mM
EDTA, 1 mM DTT 10% glycerol, 150 mM KCl):
CYP3A4 and CPR to a final concentration of 20 mM
each, cytochrome b5 to a final concentration of 10 mM,
CHAPS to 7.7 mM, DOPC to 0.15 mM. The reconstituted
enzyme was stored at ¢80 8C when not directly used.
2.3 Preparation of msCYP/MWCNT Electrodes
The biosensors were prepared using commercial carbon
paste SPEs (model DRP-C110, DropSens, Spain) consist-
ing of a graphite working electrode with an active area of
12.56 mm2, a graphite counter electrode and an Ag jAgCl
reference electrode. A 1-mg/mL solution of MWCNTs,
prepared in chloroform, was sonicated for 30 min to
obtain a homogeneous suspension [28]. The procedure
used to drop-cast MWCNTs and the enzyme solution on
SPEs, is described in Reference [18]. After the protein
deposition, the electrodes were stored at 4 8C overnight
to promote a homogeneous protein adsorption on the
CNT-nanostructure.
2.4 Apparatus
Electrochemical measurements were performed using an
Autolab electrochemical workstation (Metrohm, Switzer-
land). The scanning electron micrographs (SEM) were ac-
quired using a Philips/FEI XL-30F microscope (Philips,
Eindhoven, The Netherlands). The scanning electron mi-
croscope was operated in 1.5–4.2 mm ultra-high resolu-
tion mode (UHR). The resolution was 2.5 nm at 1 kV.
2.4 Electrochemical Measurements
The electrochemical response of the biosensor was inves-
tigated by CV at room temperature under aerobic and
anaerobic conditions by applying a potential sweep be-
tween ¢800 and +300 mV vs. Ag jAgCl at a scan rate of
20 mV/s. For experiments carried out under anaerobic
conditions, the 100 mM PBS solution was bubbled with
N2 for 45 minutes before measurements in a sealed elec-
trochemical cell. During the measurements, N2 was con-
tinuously fluxed on the solution surface in order to avoid
oxygen contamination and not to affect the measure-
ments.
For the sensor calibration to NAP and IFO, drug sam-
ples were added in increasing concentrations. The elec-
trode was covered with 100 mL of 100 mM PBS (pH 7.4)
and drug samples were added in 1 mL drops. Sensitivity
per unit area was calculated from the peak current that
was estimated according to the procedure reported by
[30,31]. The limit of detection (LOD) was computed as
three times the signal-to-noise ratio according to the ex-
pression [32, 33] LOD=kdi/S, where di is the standard
deviation of the blank measurements, S is the sensitivity,
and k is a parameter accounting for the confidence level
(k=1, 2, or 3 corresponds to 68.2%, 95.4%, or 99.6% of
confidence, respectively).
3 Results and Discussion
3.1 Identification of the Cathodic Reduction Peaks for
msCYP
To characterize more precisely the peaks obtained for mi-
crosomes adsorbed on MWCNTs, an analysis of the re-
duction peaks obtained in CV was carried out under sev-
eral experimental conditions: with bare or MWCNT-
modified electrodes, in aerobic/anaerobic conditions, with
two CYP isoform (msCYP1A2 and msCYP3A4) and with
purified CYP3A4.
3.1.1 Reduction Peaks of msCYP3A4 on MWCNT-
Modified or Bare Electrode
Figure 1 shows the reduction current peaks in the poten-
tial window +200/¢800 mV for five cases: for
msCYP3A4 on a MWCNT-modified SPE (A), for
a MWCNT-modified SPE without protein (B), for
msCYP3A4 on a bare-SPE (C), for msCYP3A4 on
a bare-SPE in the presence (black points) and absence
(red points) of oxygen (D) and for the purified proteins
(pCYP and pCPR) on MWCNT-modified SPEs (E).
The resolution of peak overlapping with mathematical
functions, is a procedure well known in literature [50,51],
and can be used to visualize the faradic current generated
by the various biosensor components. The basic functions
used for the decomposition are the Guassian, the Hyper-
bolic cosine and the Cauchy function [52]. More complex
functions are usually based on modifications or combina-
tions of these three.
In order to visualize the individual contributes of CNT,
CYP and CPR, we normalized the reduction current be-
tween +200 and ¢800 mV to the baseline obtained with
the automatic peak recognition software, and we used the
Gaussian functions to describe the different faradic con-
tributes. The peak position of each gaussian was initially
cantered according to the data obtained from literature
and then optimized with the fitting. The y values of each
Gaussian where then summed up, while height and ampli-
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tude where fitted to the current profile obtained from the
raw data [29].
In Figure 1 the Gaussian curves in subfigures (A-B-C-
D-E) share the same color code in order to display simi-
larities and differences between peaks. Figure 1A shows
the background-subtracted reduction peaks from the CV
for msCYP3A4 adsorbed on a MWCNT-modified-SPE.
We observe four different peaks in the reduction region:
at ¢540 mV, at ¢360 mV, at around ¢200 mV and at
¢50 mV. Figure 1B shows the background-subtracted re-
duction peaks from the CV for a MWCNT-modified SPE
without protein. Figure 1C reports the background-sub-
tracted reduction peaks for msCYP3A4 on a bare-SPE.
For msCYP3A4 on bare electrodes only two reduction
peaks were observed and fitted with two Gaussian func-
tions: at ¢540 mV and ¢360 mV.
With both bare and MWCNT-modified electrodes, we
observed two reduction peaks in the region ¢300/
¢600 mV: one reduction peak at ¢360 mV and one at
¢540 mV. The reduction peak at ¢360 mV is due to the
electron transfers to CYP, while the peak at ¢540 mV
can be attributed to the reduction of CPR. Positions of
peak potentials are in good agreement with the peak po-
sitions reported in recent studies on microsomes contain-
ing CYP and CPR [9,10], where the authors showed that
in CV both CYP and CPR give a contribution in the
form of reduction peaks. In particular, the authors in [10]
showed for microsomal CYP3A4 a CYP reduction peak
at ¢380 mV and a CPR reduction peak at ¢420 mV. The
potential peak for CPR was confirmed in other individual
electrochemical studies [34].
We attributed the peak at around ¢200 mV to the re-
duction of the carboxyl groups of carbon nanotubes [35]
as shown in Fig.1B (SPE is modified with MWCNTs,
without proteins). In Figure 1A, the CNT-peak (gray line)
at ¢200 mV displays a lower current, because the micro-
somal components cover the MWCNTs. The peak at
¢50 mV (labeled as “BKG”) can be attributable to the
reduction of other microsomal components [36].
This peak is also present for the msCYP on a bare-
SPE, but it is not present anymore after background sub-
traction (Figure 1C). From Figure 1, it is evident that the
presence of carbon nanotubes increases the reduction cur-
rent for the microsomal component CYP: the CYP reduc-
tion peak current value is significantly larger than the
CPR peak, for the MWCNT-SPE (Figure 1A), respect to
the bare SPE (Figure 1C). This carbon nanotube effect in
enhancing the reduction current will be discussed in Sec-
tion 3.2.
3.1.2 Reduction Peaks of msCYP3A4 in Aerobic/
Anaerobic Conditions
To characterize more precisely the peaks obtained for mi-
crosomes adsorbed on MWCNTs, voltammetric responses
of msCYP3A4 were studied in substrate-free PBS in
aerobic/anaerobic conditions. In agreement with previous
findings [3,10,11], we expected a decrease in the cathodic
current peak of the microsomal component CYP upon
the depletion of oxygen from the solution.
In Figure S1 (Supporting Information) the whole vol-
tammograms for msCYP3A4 on bare-SPE (A) and
a MWCNT-SPE (B) are reported, in aerobic and anaero-
bic conditions. In absence of O2 we can observe the oxi-
dation peak for the microsomal component CYP that oth-
erwise would be completely attenuated in the presence of
O2 in the solution [5]. Figure S2 (Supporting Information)
shows the background-subtracted oxidation and reduction
peaks for msCYP3A4 on a bare SPE in anaerobic condi-
tions. This evaluation of the CV peaks revealed that the
oxidation peak current is slightly smaller than the corre-
sponding reduction peak. This can be ascribed to the
presence of traces of oxygen due to an imperfect sealing
of the buffered solution and to the low scan rate (20 mV/
s) that makes the oxidation peak more difficult to observe
[11].
Figure 1D shows the background-subtracted reduction
peaks from the CV for msCYP3A4 on a bare-SPE in an
N2-saturated buffered solution (blue dots, labeled as
“N2”) and in aerobic conditions (black dots, labeled as
“O2”). Figure 1D shows a clear decrease of the cathodic
current at ¢360 mV when oxygen is depleted from the so-
lution, and a subsequent increase of cathodic current
back to the initial value when aerobic conditions are es-
tablished again (black dots, labeled as “O2”). The increase
of the cathodic current in presence of oxygen is character-
istic for the electrochemical response of heme-containing
proteins such as CYP [10,11], hemoglobin [37] and myo-
globin [35]. In conclusion we confirm that the cathodic
peak at ¢360 mV is ascribed to the reduction of the mi-
crosomal component CYP.
3.1.3 Purified CYP3A4 and CPR
To further confirm that the peak at ¢360 mV can be at-
tributed to the reduction of the microsomal component
CYP, voltammetric measurements on MWCNT-SPE were
carried out with two preparations of purified proteins:
pCYP3A4 (without CPR) and pCPR (without CYP). Fig-
ure 1E shows the background-subtracted reduction peaks
from the CV for the purified proteins (pCYP and pCPR)
on MWCNT-modified SPEs. pCPR (red dots) gives
a well-defined reduction peak at ¢550 mV, while the
pCYP3A4 (black dots) gives a reduction peak at
¢240 mV. It is positively shifted by 100 mV with respect
to the msCYP3A4, thus making it overlapping with the
reduction peak of CNTs. This may be due to the absence
of other microsomal components (CPR, lipids). However,
the potential of the reduction peak of pCYP3A4 is in
good agreement with previous studies on purified pro-
teins [19,21].
Voltammetric experiments on MWCNT-SPEs were also
conducted with two preparations of reconstituted pro-
teins: recCYP3A4 (without CPR) and recCPR (without
CYP3A4) and the results are reported in Figure S3 (Sup-
porting Information). With recCYP3A4 (black dots) we
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can identify the peak at ¢380 mV similar to the peaks
found for msCYP3A4 on MWCNT-SPE (Figure 1A). The
peak at ¢540 mV is not present while it is clearly visible
in the reduction region of the recCPR (red dots), thus
confirming the previous results.
3.1.4 Reduction Peaks of msCYP1A2
We performed similar experiments also with msCYP1A2,
as illustrated in Figure S4 in the Supporting Information.
The only difference is that the microsome peaks are posi-
tively shifted by 20 mV: the CYP peak is centered at
¢380 mV (red line) and the CPR peak at ¢560 mV
(orange line).
To further confirm that the cathodic peak at ¢380 mV
can be attributed to the reduction of the heme protein i.e.
the CYP component of microsome, CV was performed in
the presence of increasing concentrations of hydrogen
peroxide (H2O2), since it has been reported that proteins
containing a heme group, such as CYP [9,10], hemoglo-
bin [35,37], myoglobin [35] and horseradish peroxidase
[38], can catalyze the reduction of H2O2.
In all the cited studies a large cathodic current for the
reduction of H2O2 appears at the reduction potential of
the heme protein, while the anodic peak disappears com-
pletely. With our msCYP we observed the same behavior:
Figure S5 (Supporting Information) shows the reduction
peaks after the background subtraction for the
msCYP1A2-bare SPE in presence of H2O2 at different
concentrations (1 and 5 mM). When H2O2 is added, the
msCYP1A2-bare SPE shows a large reduction peak at
around ¢380 mV that increases with the concentration of
H2O2 in solution. With the same H2O2 concentrations we
observe a smaller increase in reduction current for
a bare-SPE, without the enzyme.
3.2 Enhancement of Reduction Current of Microsomal
CYP with MWCNTs on SPE
To better understand the improvement in the electro-
chemical reactivity of the protein when it is adsorbed on
MWCNTs, we estimated the surface concentration of the
electroactive CYP1A2 and CYP3A4 on the electrode, G
(in mol/cm2). G can be estimated using the equation G=
Q/nFA, where Q is the charge consumed (in C), obtained
from integrating the cathodic peak area in CV after the
background correction (divided by the scan rate), n is the
number of electrons exchanged in the redox (n=1) [11],
A the electrode area (0.1256 cm2) and F the Faraday con-
stant (in C mol¢1) [39].
The values of G for CYP1A2 and CYP3A4 on bare and
MWCNT-coated electrodes are reported in Table 1. The
values of G were calculated for a scan rate of 20 mV/s.
The total amount of proteins drop-cast on the electrode is
3.98 nmol/cm2 (estimation, from vials of ~ 0.5 nmol, on
electrodes with area equal to 0.1256 cm2). From the data
presented in Table 1, only a part of the CYP on the elec-
trode surface undergoes the direct electron transfer reac-
tion. The fraction of electroactive CYP over the total ad-
sorbed protein on the MWCNT-modified electrode is
80% for CYP1A2 and 83% for CYP3A4. These values
are higher than the 54.7% obtained for hemoglobin im-
mobilized on a Nafion-CNT electrode [37], and other
heme-containing proteins immobilized in surfactant or
polymers [40], indicating that MWCNTs are very effec-
tive in promoting the direct electron transfer of CYP, as
has already been found in [35,37]. This is also confirmed
by the smaller fractions of electroactive msCYP obtained
when bare electrodes are used instead of the MWCNT-
coated electrodes, which is 27% for CYP1A2 and 61%
for CYP3A4. We observed a large variation in the frac-
tion of electroactive CYP on bare electrode due to the
unstable immobilization of the protein on the electrode
surface.
MWCNTs have been recognized as promising nanoma-
terials for facilitating electron transfer in biosensing [41],
because of their electrical and electrochemical properties:
small size with large surface area, high conductivity, high
chemical stability and sensitivity [42,43]. MWCNTs en-
hance the electrochemical reactivity of proteins or en-
zymes probably due to the presence of some oxygen-con-
tained groups (e.g. carboxyl groups) [37] on the carbon-
nanotube surface.
Moreover, MWCNTs create a hydrophobic and highly
electroactive surface when they are drop-cast on electro-
des, as already shown in our previous works [28,31].
We obtained higher values of G than for bare-SPE, due
to the increase in electroactive area of the electrode due
to MWCNTs that creates a three-dimensional porous
structure with a larger effective surface area available for
protein deposition as shown in the SEM of Figure 2. Fig-
ure 2A shows the SEM of the surface of a graphite SPE
after the deposition of 30 mg of MWCNTs, acquired with
an 8000×magnification, where the three-dimensional
structure of the MWCNT agglomerate is shown. Fig-
ure 2B shows a SEM acquired at the same surface of
MWCNT-SPE at higher magnification (80 000×). The en-
hancement of the CYP electrochemical reactivity after
adsorption on MWCNTs results in higher peak currents
for the microsomal component CYP as shown in Figure 1.
Table 1. G of electroactive enzyme and percentage relative to the total amount of deposited protein.
CYP isoform G of electroactive CYP (nmol/cm2) Electroactive protein (%)
BARE SPE MWCNT-SPE BARE SPE MWCNT-SPE
CYP1A2 1.070.04 3.20.1 27 80
CYP3A4 2.420.09 3.770.15 61 83
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The MWCNT-enhancement in msCYP reduction cur-
rent has been shown with a comparative experiment for
msCYP/MWCNT-SPE and msCYP-bare SPE in presence
of increasing concentrations of a drug. The measured
drugs are, for CYP1A2, Naproxen (NAP), an anti-inflam-
matory agent with analgesic and antipyretic properties
[44], and, for CYP3A4, Ifosfamide (IFO), a widely used
anti-cancer drug [45]. Both NAP and IFO were measured
in therapeutic concentrations: 10–160 mM for IFO [46]
and 9–300 mM for NAP [47].
Figure 3 shows peak reduction current values obtained
for msCYP3A4-bare SPEs (Figure 3A), and for
msCYP3A4/MWCNT-SPEs (Figure 3B) for increasing
concentrations of IFO. Figure 3C and Figure 3D show the
peak reduction current values for msCYP1A2-bare SPE
and msCYP1A2/MWCNT-SPE respectively, in the pres-
Fig. 2. Comparison of typical SEM of the surface of a graphite SPE after the deposition of 30 mg of MWCNTs, acquired with an
8000X magnification (A) and with an 80000 magnification (B).
Fig. 3. Reduction current peaks from CV after background subtraction for a msCYP3A4-bare SPE (A) and for a msCYP3A4/
MWCNT-SPE (B) at increasing concentration of IFO; Reduction current peaks from CV after background subtraction for
a msCYP1A2-bare SPE (C) and a msCYP1A2/MWCNT-SPE (D) for increasing concentrations of NAP.
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ence of increasing concentrations of NAP. In the y-dimen-
sion, reduction currents obtained from CV are shown
after background subtraction and the normalization with
respect to the voltammogram obtained in PBS in the ab-
sence of drug. The normalization was done in order to
show only peaks that were increasing after the addition
of drug. Figure S6 (Supporting Information) shows the
whole voltammogram for the msCYP1A2/MWCNT-SPE
sensor at different NAP concentrations. The addition of
a substrate, e.g. a drug, results in a further increase of the
CYP reduction current proportional to the substrate con-
centration [11]. This phenomenon has been verified for
a number of different CYPs immobilized onto electrodes,
such as CYP2C9 [12], CYP2B4 [11,17], CYP3A4 [19],
CYP2B6 [48], CYP2D6 [49], and CYP1A2 [14,16]. This
was verified, in our recent work, for msCYP1A2 in the
presence of Naproxen [18].
As we expected, the reduction peak current of the mi-
crosome-CYP component shown in Figure 3 (highlighted
in red) linearly increases with drug concentration. The in-
crease in current is more evident with msCYPs adsorbed
to a MWCNT-modified SPE, than to a bare-SPE. Also
the peak of the CPR component shows a slight increase,
but less significant.
Control experiments were performed with methanol
and milliQ instead of drug and we could confirm that the
voltammograms for msCYP/MWCNT-SPE did not show
any significant change (data not shown).
From the peak currents at different drug concentrations
reported in Fig.3, we obtained the calibration curves.
Table 2 reports an overview of sensitivity and limit of de-
tection (LOD) obtained from the calibration curves: for
NAP detection with msCYP1A2 and for IFO detection
with msCYP3A4.
As shown in Table 2, with msCYP-bare SPEs there is
generally lower sensitivity, higher data variability and
noise, resulting in a lower linearity, higher uncertainty in
the estimation of LOD and higher LOD, with respect to
the msCYP/MWCNT-SPE sensors. This shows that
MWCNTs greatly enhance electron transfer between
electrode and msCYP.
In conclusion, this comparative study shows that
MWCNTs improve the sensor performance in both stud-
ied microsomal systems (the CYP isoforms 1A2 and
3A4).
Both msCYP1A2 and msCYP3A4 on a MWCNT-SPE
exhibited a wide linear range and a sensitivity acceptable
for detection of NAP and IFO respectively. Sensitivity
and LOD values proved that drug detection in the thera-
peutic range has been successfully achieved due to the
synergistic effect of msCYP and MWCNTs in enhancing
the reduction current.
4 Conclusions
In this work, we demonstrated that: 1) with voltammetric
measurements in several experimental conditions we can
clearly identify the reduction peak for each CYP compo-
nent of microsomes, which is essential to measure drug
concentrations; 2) with MWCNTs we have more electro-
active enzyme adsorbed on the electrode as compared to
a bare electrode; 3) this results in a better definition of
all peaks obtained in voltammetry that refer to different
microsomal components, also in a complex system such as
microsomes containing CYP and CPR; 4) the enhance-
ment of the reduction current of msCYP by carbon nano-
tubes results in an improvement in the sensing perfor-
mance of drugs.
Moreover, we proved that the hydrophobic surface cre-
ated by MWCNTs can actively drive the electrochemical
detection of drugs more efficiently than the unmodified
SPE. In conclusion, MWCNTs could represent an ideal
electrode modification to greatly enhance the sensor per-
formance by improving the electron transfer to the pro-
tein and by retaining the activity of CYP toward drugs.
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